Botox dilution for hyperhidrosis is the clearest worked example in aesthetic medicine of using concentration deliberately — and it runs in exactly the opposite direction from everything an injector learns doing precision perioral work. Where the depressor anguli oris corridor demands the tightest concentration an injector can accurately draw, the axilla demands the opposite: a dilute preparation whose whole purpose is to cover territory.
Dr. Chris Croley, Chief Medical Officer at Empire Medical Training, sets out the reasoning in Empire's reconstitution curriculum:
"When we start talking about areas like hyperhidrosis or sweating... in those situations, we want that neurotoxin to spread out over a wide surface area, so we get the effect of it. So how do we deliver those number of units over a wide surface area? We put more fluid. So that is going to be when we start varying our dilution and doing something a little more dilute."
He covers it briefly, as an illustration of the principle. It is worth more than a passing mention, because unlike most dilution decisions in aesthetics this one has an on-label answer, a pivotal trial behind it, and a dose-response finding that changes how you think about the whole treatment.
The target is a surface, not a muscle
Everything that makes wide-field dilution correct here follows from what you are actually treating.
Botulinum toxin blocks acetylcholine release at the neuromuscular junction, and it blocks it equally at the cholinergic sympathetic terminals that innervate eccrine sweat glands. In facial aesthetics you are chemodenervating a discrete muscle belly with a defined origin and insertion. In the axilla you are chemodenervating a two-dimensional distribution of glands spread across a patch of skin, at a depth measured in fractions of a millimetre, with no anatomical boundary marking where the affected region should end.
That difference dictates everything. There is no "the muscle" to hit. There is only territory to cover, and the failure mode is not overreach into a neighbour — it is a patch you missed, which the patient will find within a fortnight.
What the label actually specifies
The BOTOX label carries an indication for severe primary axillary hyperhidrosis inadequately managed with topical agents, and its instructions are unusually specific. This section is label data, not Dr. Croley's taught practice, and the distinction is worth keeping:
- Reconstitution: 100 Units in 4 mL of preservative-free 0.9% Sodium Chloride Injection, USP — a concentration of 2.5 Units per 0.1 mL.
- Dose: 50 Units per axilla, which at that concentration is 2 mL of reconstituted solution per side.
- Delivery: intradermally, using a sterile 30 gauge needle.
- Distribution: 0.1 to 0.2 mL aliquots evenly distributed across 10 to 15 sites, approximately 1 to 2 cm apart.
- Mapping: the hyperhidrotic area should be defined using a standard staining technique such as Minor's iodine-starch test.
- Retreatment: when the clinical effect of the previous injection diminishes.
The label's Minor's test instructions are equally concrete: patients shave the underarms and abstain from over-the-counter deodorants and antiperspirants for 24 hours before the test, and rest comfortably without exercise or hot drinks beforehand.
Set that against the BOTOX label's facial dilution rows, where the same 100 Unit vial is reconstituted in 1 mL or 2 mL for concentrated work, and the design intent is obvious. The 4 mL reconstitution exists so that 2 mL of fluid can be distributed across an axilla in aliquots large enough to spread between widely spaced points.
Why 0.1 to 0.2 mL per site is the real lever
The instructive detail in that label is not the reconstitution volume by itself. It is the combination of a dilute preparation, a large per-site aliquot, and points 1 to 2 cm apart.
An injector placing 10 to 15 points across an axilla cannot rely on point density alone to cover the field — 1 to 2 cm of untreated skin sits between every pair of injections. The aliquot has to bridge that gap. A 0.1 to 0.2 mL deposit spreads laterally through the dermis from each point, and the overlapping fields are what produce a continuous region of anhidrosis rather than a polka-dot pattern.
This is the same physics that makes a large volume dangerous beside the depressor labii inferioris, deployed on purpose. Hsu, Dover and Arndt demonstrated in Archives of Dermatology in 2004 that an identical 5 Unit dose delivered in 0.25 mL rather than 0.05 mL produced a roughly 50% larger area of effect. In the face that enlargement is a liability. In the axilla it is the mechanism of action at a clinical level.
The dose-response finding that should change your planning
The pivotal trial data in the BOTOX label contains a result worth reading carefully, because it argues against the instinct to push the dose.
In the first randomised, multi-centre, double-blind, placebo-controlled study, 322 adults with persistent primary axillary hyperhidrosis scoring 3 or 4 on the Hyperhidrosis Disease Severity Scale — and producing at least 50 mg of sweat per axilla at rest over five minutes — were randomised 1:1:1 to 50 Units, 75 Units or placebo in both axillae.
Responder rates for at least a 2-grade improvement in HDSS were 55% at 50 Units, 49% at 75 Units and 6% for placebo. For a greater than 50% reduction in gravimetrically measured sweat production, rates were 81%, 86% and 41% respectively. Both toxin groups were significantly better than placebo (p<0.001), and — the important part — the two dose groups were not significantly different from each other.
Median duration of response after the first treatment was 201 days at either dose, with a similar duration after a second injection.
Two conclusions for planning. First, a 50% increase in dose bought nothing measurable, so there is no evidence-based case for escalating units when a patient responds incompletely. Second, if a patient under-responds, the variable worth interrogating is coverage — was the hyperhidrotic field correctly mapped, were the points spaced to allow overlap, was the depth genuinely intradermal — rather than dose. The failure is far more likely to be a geography problem than a pharmacology problem.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
That reframing is the practical payoff of understanding dilution as a coverage instrument.
Intradermal is not a detail
The label's specification of intradermal delivery with a 30 gauge needle is not incidental. Eccrine glands sit in the deep dermis. Fluid deposited too deep enters subcutaneous fat and underlying muscle, where it is both less effective against the target and more likely to produce the compensatory weakness that has been reported with injections in this region.
An intradermal injection in the axilla should produce a visible bleb. If it does not, the needle is too deep. That single observable is worth more than any amount of technique description, and it is one of the reasons hands-on supervision matters for this treatment.
The dilute preparation helps here too. A 0.1 to 0.2 mL intradermal deposit raises an obvious wheal; the same number of units in 0.02 mL would not, and the injector would lose their feedback signal.
Mapping before dosing
Minor's iodine-starch test is the step most often skipped and the one that most directly determines the result, given the trial finding above.
Iodine solution is applied to the dry axilla and allowed to dry, then starch powder is dusted over it. Where sweat is produced, the iodine-starch reaction turns the area a deep blue-black, and the visible stain defines the hyperhidrotic field. That field is what gets injected — not a standard rectangle, not the hair-bearing area, and not a shape estimated by eye.
The label's preparation instructions matter to the result: shaving, 24 hours without antiperspirant or deodorant, and a resting patient without recent exercise or hot drinks. A test run on a patient who applied antiperspirant that morning will under-map the field, and an under-mapped field is an under-treated axilla.
What this teaches about dilution generally
Axillary hyperhidrosis and the perioral corridor are the two ends of the same instrument, and holding both in mind is what turns reconstitution from a habit into a decision.
| Perioral / DAO corridor | Axillary hyperhidrosis | |
|---|---|---|
| Target | Discrete thin muscle | Two-dimensional gland field |
| Neighbour risk | High — DLI millimetres away | Low within the mapped field |
| Failure mode | Spread into a protected muscle | Missed territory |
| Concentration | Concentrated | Dilute (label: 2.5 Units/0.1 mL) |
| Aliquot | As small as accurately deliverable | 0.1 to 0.2 mL |
| Plane | Intramuscular | Intradermal |
Same drug. Same arithmetic. Opposite answers, because the question is different.
Dr. Croley's teaching on varying dilution for wide-field indications reflects his clinical practice as taught in Empire Medical Training's hands-on curriculum. The specific reconstitution, dose, aliquot and site figures in this article are taken from the BOTOX prescribing information and are identified as label data. Technique is learned under supervision; this article is educational and is not a substitute for training.
Injectors adding hyperhidrosis to an aesthetic practice can work through preparation, mapping and intradermal technique with supervision in Empire's Cosmetic Neurotoxins Training and Complete Botox Training workshops. Empire's injection site mapping material and Complete Facial Aesthetic Training cover the facial side of the same principle.
Frequently Asked Questions
What dilution does the label specify for axillary hyperhidrosis?
The BOTOX label specifies reconstituting a 100 Unit vial with 4 mL of preservative-free 0.9% sodium chloride, giving 2.5 Units per 0.1 mL. The recommended dose is 50 Units per axilla, which at that concentration is 2 mL of solution per side, delivered intradermally in 0.1 to 0.2 mL aliquots across 10 to 15 sites approximately 1 to 2 cm apart.
Is a higher dose more effective for hyperhidrosis?
The pivotal trial randomised patients to 50 Units, 75 Units or placebo per axilla. Both toxin doses were significantly better than placebo, but the two doses were not significantly different from each other on either HDSS improvement or gravimetric sweat reduction. There is no trial evidence supporting dose escalation above the labelled 50 Units.
How long does axillary hyperhidrosis treatment last?
In the pivotal study, median duration of response after the first treatment was 201 days at both the 50 Unit and 75 Unit doses, and duration after a second injection was similar. Retreatment is indicated when the clinical effect of the previous injection diminishes.
Why does hyperhidrosis treatment use a dilute preparation when facial work often does not?
Because the target is a surface rather than a muscle belly. Points are placed 1 to 2 cm apart, so each 0.1 to 0.2 mL aliquot must spread laterally through the dermis to meet its neighbours. A concentrated preparation delivering the same units in a fraction of the volume would leave untreated gaps between points.
Why is Minor's iodine-starch test worth the extra step?
Because it defines the field you are treating. Iodine and starch turn the actively sweating area blue-black, showing the true hyperhidrotic distribution rather than an estimate. Given that trial data shows no benefit from higher doses, accurate mapping is the variable most likely to determine whether a patient responds.
Disclaimer
This article reflects the clinical opinions and experience of Dr. Chris Croley, Chief Medical Officer, Empire Medical Training, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
